Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-HyperCVAD/MTX-AraC + Zevalin in MCL
NCT00505232Phase 2Completed
- Sponsor
- CABYC
- Start
- Jan 2006
- Primary completion
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in mantle cell lymphoma (MCL), sponsored by CABYC. Started Jan 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00505232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505232.